Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer

Phase 2

Conditions: Stage III Pancreatic Cancer
Adenocarincoma of Pancreas
Stage IVB Pancreatic Cancer
Stage IVA Pancreatic Cancer

First Posted Date: 2006-05-09

Last Posted Date: 2007-05-08

Lead Sponsor: Seattle Cancer Treatment and Wellness Center

Target Recruit Count: 80

Registration Number: NCT00323583

Locations: 🇺🇸
Seattle Cancer Treatment and Wellness Center, Seattle, Washington, United States

Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Biological: bevacizumab
Drug: fluorouracil
Drug: leucovorin
Drug: oxaliplatin

First Posted Date: 2006-05-04

Last Posted Date: 2024-03-21

Lead Sponsor: NSABP Foundation Inc

Target Recruit Count: 90

Registration Number: NCT00321828

Locations: 🇺🇸
Kaiser Permanente Medical Center - Redwood City, Redwood City, California, United States
🇺🇸
Meeker County Memorial Hospital, Litchfield, Minnesota, United States
🇺🇸
Great Falls Clinic - Main Facility, Great Falls, Montana, United States

and more 159 locations

Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer

Phase 2

Completed

Conditions: Stage II Rectal Cancer AJCC v7
Stage III Rectal Cancer AJCC v7
Rectal Adenocarcinoma

Interventions: Biological: Bevacizumab
Drug: Capecitabine
Drug: Fluorouracil
Drug: Leucovorin Calcium
Drug: Oxaliplatin
Radiation: Radiation Therapy
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2006-05-04

Last Posted Date: 2019-03-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 57

Registration Number: NCT00321685

Locations: 🇺🇸
Einstein Medical Center Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Sparta Cancer Treatment Center, Sparta, New Jersey, United States
🇺🇸
Nebraska Cancer Research Center, Lincoln, Nebraska, United States

and more 104 locations

IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer

Phase 3

Suspended

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: L-Plat
Drug: Campto, Topotesin
Drug: Isovorin
Drug: TS-1
Drug: 5-FU

First Posted Date: 2006-04-21

Last Posted Date: 2007-11-01

Lead Sponsor: Hokkaido Gastrointestinal Cancer Study Group

Target Recruit Count: 200

Registration Number: NCT00316745

Locations: 🇯🇵
Hokkaido University Hospital (Hokkaido University Graduate School of Medicine / School of Medicine), Sapporo, Hokkaido, Japan

Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer

Phase 2

Completed

Conditions: Anal Cancer

Interventions: Biological: cetuximab
Drug: cisplatin
Drug: fluorouracil
Radiation: radiotherapy

First Posted Date: 2006-04-21

Last Posted Date: 2023-06-29

Lead Sponsor: ECOG-ACRIN Cancer Research Group

Target Recruit Count: 63

Registration Number: NCT00316888

Locations: 🇺🇸
Borgess Medical Center, Kalamazoo, Michigan, United States
🇺🇸
Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States
🇺🇸
Greater Baltimore Medical Center Cancer Center, Baltimore, Maryland, United States

and more 122 locations

Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery

Phase 3

Completed

Conditions: Breast Cancer

First Posted Date: 2006-04-06

Last Posted Date: 2013-06-26

Lead Sponsor: Gruppo Italiano Mammella (GIM)

Target Recruit Count: 280

Registration Number: NCT00311636

Locations: 🇮🇹
Ospedale Civile, Castelfranco - TV, Italy
🇮🇹
Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
🇮🇹
Ospedale Sant Anna, Como, Italy

and more 15 locations

Combination Chemotherapy With or Without Darbepoetin Alfa in Treating Women With Stage III Breast Cancer

Not Applicable

Conditions: Breast Cancer

First Posted Date: 2006-04-03

Last Posted Date: 2009-02-09

Lead Sponsor: Heinrich-Heine University, Duesseldorf

Target Recruit Count: 1234

Registration Number: NCT00309920

Locations: 🇩🇪
Knappschaft Krankenhaus, Bochum-Langendreer, Germany
🇩🇪
Praxis Fuer Haematologie Internistische Onkologie, Cologne, Germany
🇩🇪
St. Elisabeth-Krankenhaus - Koeln, Cologne, Germany

and more 44 locations

Randomized Trial on Adjuvant Chemotherapy in Colon Carcinoma Dukes B

Phase 3

Completed

Conditions: Colon Cancer Stage II

First Posted Date: 2006-04-03

Last Posted Date: 2006-04-03

Lead Sponsor: Austrian Breast & Colorectal Cancer Study Group

Target Recruit Count: 636

Registration Number: NCT00309543

Locations: 🇦🇹
Hospital Hainburg, Hainburg, Lower Austria, Austria
🇦🇹
Hospital Oberpullendorf, Oberpullendorf, Burgenland, Austria
🇦🇹
Medical University Vienna, General Hospital, Vienna, Austria

and more 15 locations

Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients

Phase 3

Completed

Conditions: Early Stage Breast Cancer

Interventions: Drug: Cyclophosphamide
Drug: Methotrexate
Drug: Fluorouracil
Drug: Epirubicin
Other: Surgery

First Posted Date: 2006-04-03

Last Posted Date: 2020-10-14

Lead Sponsor: Austrian Breast & Colorectal Cancer Study Group

Target Recruit Count: 429

Registration Number: NCT00309569

5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer

Phase 2

Completed

Conditions: Rectal Cancer
Cancer of the Rectum
Colorectal Cancer

Interventions: Drug: 5-Fluorouracil
Drug: Bevacizumab
Procedure: Radiation Therapy
Drug: Oxaliplatin
Drug: Leucovorin

First Posted Date: 2006-03-29

Last Posted Date: 2021-12-10

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 66

Registration Number: NCT00308516

Locations: 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
Northeast Arkansas Clinic, Jonesboro, Arkansas, United States
🇺🇸
Northeast Alabama Regional Medical Center, Anniston, Alabama, United States

and more 11 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy